ArticlePaediatric drugs2026
Impact of the Time to Initiation of Indomethacin or Ibuprofen on Patent Ductus Arteriosus Closure Rates.
Article in Paediatric drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur objective was to describe the clinical impact of time to initiation of indomethacin or ibuprofen on patent ductus arteriosus (PDA) closure rates in preterm neonates.
methodsThis was a retrospective cohort study including preterm neonates who received at least one dose of intravenous indomethacin or ibuprofen as their first treatment course for PDA closure. Patients were categorized into the early treatment (ET) cohort if pharmacologic therapy was initiated on day of life (DOL) 0-7 and to the late treatment (LT) cohort if initiated on DOL 8 or later. PDA closure rate was the primary outcome, and data were also evaluated to assess the need for additional medical or surgical interventions for PDA closure, as well as neonatal safety outcomes based on time to initiation of therapy.
resultsA total of 97 patients with a median gestational age of 25 weeks were included for analysis, with 29 in the ET cohort and 68 in the LT cohort. Baseline characteristics were similar between the ET and LT cohorts, with a median DOL of therapy initiation of 5 (interquartile range 4-6) and 11 (interquartile range 10-13.5) days, respectively. Rates of indomethacin as the initial nonsteroidal anti-inflammatory drug choice were similar between the ET and LT cohorts (66% vs 56%, p = 0.5). There was no difference in PDA closure rates following the initial course of pharmacologic therapy between the ET and LT cohorts (45% vs 32%, p = 0.26). Similarly, there was no difference in the incidence of a second pharmacologic treatment course (25% vs 26%, p = 1), surgical ligation, transcatheter closure, or adverse neonatal outcomes between cohorts.
conclusionThe time to initiation of intravenous indomethacin or ibuprofen did not significantly affect PDA closure rates, the need for subsequent PDA pharmacotherapy, or adverse neonatal outcomes. Overall rates of PDA closure with pharmacologic intervention were low.
Indexed as
Identifiers
41083809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.